Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DMTX

Dimension Therapeutics (DMTX) Stock Price, News & Analysis

Dimension Therapeutics logo

About Dimension Therapeutics Stock (NASDAQ:DMTX)

Advanced Chart

Key Stats

Today's Range
$5.95
$5.95
50-Day Range
N/A
52-Week Range
$1.05
$6.10
Volume
N/A
Average Volume
150,214 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Receive DMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dimension Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMTX Stock News Headlines

Trump’s Secret Social Security Plan?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
Pitch dimensions
KAYS - Kaya Holdings, Inc.
Anime Dimensions Codes (January 2023)
See More Headlines

DMTX Stock Analysis - Frequently Asked Questions

Dimension Therapeutics, Inc. (NASDAQ:DMTX) announced its earnings results on Monday, November, 6th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.20. The biotechnology company earned $4.48 million during the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dimension Therapeutics investors own include Palatin Technologies (PTN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Aquinox Pharmaceuticals (AQXP), Bellicum Pharmaceuticals (BLCM) and Can-Fite BioPharma (CANF).

Company Calendar

Last Earnings
11/06/2017
Today
4/26/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:DMTX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:DMTX) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners